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Abstract 
Background: Numerous inflammatory mediators seem to play a pathogenic role in coronary artery disease, 
promoting atherogenesis and plaque destabilization, leading to thrombus formation with development of this 
disease. The effects of the RANKL/OPG system, like modulation of cell survival and inflammation, make it an 
elect mediator in the progression of atherosclerotic lesions. 
Objectives: To estimate the role of RANKL and OPG and their relative ratio (RANKL\OPG) in pathogenesis of 
acute coronary syndrome. 
Subjects and Methods: Sixty patients with acute coronary syndrome were enrolled in this study, those patients 
were divided into two groups: 31 patients were with unstable angina (UA) and 29 patients were with myocardial 
infarction (MI), the latter group also subdivided into [18 with ST segment elevation myocardial infarction 
(STEMI) and 11 with non-ST-segment elevation myocardial infarction (NSTEMI)], their ages range from 25-83 
years. Twenty apparently healthy volunteers their ages and sexes were matched with the patients were also 
participated in the study. ELISA was carried out for estimation the serum levels of RANKL and OPG in the 
studied groups. 
Results: There was no significant difference (p>0.05) in median of serum levels of RANKL between patients 
and control. In addition the comparison among the three groups of patients (NSTEM1, STEM1 and UA) showed 
no significant differences (p>0.05) in RANKL level. Whereas the OPG level was significantly higher (p<0.001) 
in patients than that in healthy control, and there was significant increase in median serum level of OPG in the 
three patients groups as compared to control. On the other hand, there were no significant differences (p>0.05) in 
median serum levels of OPG among patients groups. The ratio of RANKL / OPG was significantly increase 
(P<0.001) in healthy control as compared to patients. The median of RANKL / OPG ratios in NSTEM1, STEM1 
and UA patients groups were significantly lower (P<0.001) when compared to the ratio in healthy control. In 
contrast there were no significant differences in ratio among patients groups (p>0.05). 
Conclusion: These findings indicated that there was high significant elevation in serum level of OPG in acute 
coronary syndrome, so, it enforce the clinical utility of OPG in atherosclerosis and suggested that RANKL/OPG 
ratio could be a biomarker for acute coronary syndrome. 
Keywords: Acute coronary syndrome, RANKL, OPG. 
 
1. Introduction 
Acute coronary syndrome usually occurs as a result of one of three problems: unstable angina (UA), non–ST-
segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI). 
These types are named according to the appearance of the electrocardiogram (Torres and Moayedi, 2007). Since 
the early 1900s cardiovascular disease (CVD) has been the leading cause of death (Dallas et al., 2002). Among 
men, risk increases with each decade of age and comparisons between men and women demonstrate that for 
premenopausal women the risk corresponds with that of men approximately 10 years younger (British Heart 
Foundation and Coronary Heart Disease Statistics, 2004).  
Cytokines are released by the host myocardium to modulate tissue repairs and adaptation after injury. 
The osteoprotegerin (OPG)/ Receptor activator of nuclear factor-kappa B ligand (RANKL)/ Receptor activator 
of nuclear factor-kappa B (RANK) axis has been implicated in various inflammatory responses and has also 
been linked to atherogenesis (Sandberg et al., 2006). RANKL/RANK/OPG system has an important role in 
several aspects of the processes leading to calcification (Anand et al., 2006). RANKL binds to its membrane 
receptor RANK and produces several intracellular signals that regulate the fusion, development, function, and 
survival of the osteoclasts (Abedin et al., 2004; Anand et al., 2006). 
OPG is a soluble member of the tumor necrosis factor receptor superfamily with pleiotropic effects on 
bone metabolism, endocrine function, and the immune system (Simonet et al., 1997). OPG inhibits 
osteoclastogenesis by binding the receptor activator of nuclear factor RkRB ligand (RANKL), acting as a decoy 
receptor to competitively inhibit RANKL interaction with its receptor, RANK (Boyle et al., 2003). OPG can be 
detected in atherosclerotic lesions (Sandberg et al., 2006), and in humans elevated circulating OPG 
concentrations have been associated with aortic plaque (Abedin et al., 2007), as well as with increased 
prevalence and severity of coronary artery disease (Anand et al., 2006).Thus, the aim of this study is to provide 
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insight into the potential role of this RANKL/OPG system in the pathogenesis of ACS. 
2. Subjects and Methods 
Patients 
Sixty Patients presented with chest pain or typical symptoms suggestive for ischemic heart disease (IHD) 
presented to coronary care unit in Alkadhmiya teaching hospital seeking for medical help were enrolled in this 
study, their ages ranged from 25 to 83 years. The study was conducted during the period from January 2013 until 
the midst of May 2013. 
The diagnosis of each case was established by clinical examination done by a cardiologist and 
confirmed by laboratory investigations. All the patients had no complain of other chronic or systemic diseases. 
The patients were divided into two groups: myocardial infarction group: they were twenty nine patients 
classified clinically into STEMI (n=18) and NSTEMI (n=11), depending on the diagnosis of the cardiologist and 
confirmed by ECG and cardiac enzyme troponin level. The second group was unstable angina patients: they 
were thirty one patients presented to the emergency department with acute chest pain and ECG changes 
suggestive of ischemia, and then referred to CCU and thus, diagnosed as cases of unstable angina. 
The ethical committee of College of Medicine/Al-Nahrain University approved this study, and all 
samples were obtained with informed consent in accordance with the Alkadhmiya teaching hospital declaration. 
Control 
Twenty (20) apparently healthy subjects whose ages and gender were matched with patients group were 
selected as a control group. All of them received no treatment with No complaint of other chronic or systemic 
diseases. 
Serum samples were separated from the whole blood, a liquated and stored at -20ºC until used. The 
levels of RANKL and OPG were determined by using commercially available ELISA kits and performed as 
recommended in leaflet with kits (Human RANKL kit/ CUSABIO/ China; Human OPG kit/ CUSABIO/ China). 
Statistical Analysis: Frequency distribution for selected variables was done first. The outcome 
quantitative variable (RANKL and OPG) was non-normally distributed. Such variable is described by median 
and interquartile range. The difference in median of a quantitative non-normally distributed variable between 2 
groups was assessed by non-parametric test (Mann-Whitney). Among the outcome quantitative variables were 
normally distributed, and therefore conveniently described by mean, SD, SE and tested for statistical significance 
by t-test. 
 
3. Results 
The basic characteristics of patients and controls groups included in this study are presented in tables (1), no 
statistically significant differences (p>0.05) in age were existed between patients and controls (56.48±1.38 vs. 
48.20±5.80). Moreover, there was male’s predominance among patients, about (57%) of patients were males, 
while only (43%) were females, and males/females ratio was 1.3:1. Regarding the family history of disease, 22 
(37%) of patients had positive family history of CAD, while 38 (63%) showed negative family history. 
Furthermore; 22 (37%) of patients were smokers, whereas 38 (63%) of patients were non-smokers. The current 
data showed that 29 (48%) were positive for troponin enzyme and the remaining patients 31 (52%) were 
negative. 
Table-1- Descriptive characteristics of patients and controls groups 
 Control group  
N= 20 
ACS Patients group 
N= 60 
P value 
 
Age 
Range  (21-84)  (25-83)  
0.179NS Mean+ SE 48.20+5.80 56.48+1.38 a NS 
 
Gender 
Female 8 (40%) 26 (43%)  
0.790NS Male 12 (60%) 34 (57%) 
Male / Female - 1.3:1 
Family history Positive - 22(37%)  
Negative 20(100%) 38(63%) 
Smoking habit Smokers - 22(37%)  
Non smoker 20(100%) 38(63%) 
Serum troponin Positive - 29 (48%)  
Negative 20(100%) 31 (52%) 
a: comparison between ACS and healthy control group; NS= no statistical significant difference (p>0.05), 
SE=Standard Error 
       The present study showed no significant differences (p>0.05) in median serum level of RANKL 
between patients and controls (31.10 pg/ml vs. 69.25 pg/ml) and nor between patients groups (30.40 pg/ml, 
19.10 pg/ml, 42.20 pg/ml) and healthy controls. In addition the comparison among three groups of patients also 
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showed no significant differences (p>0.05), as shown in table (2). Table (3) observed highly significant 
difference (p<0.001) in OPG level between patients and controls (122.00 pg/ml vs. 48.00 pg/ml). On the other 
hand, there was significant increase (p<0.05; p<0.001) in level of OPG in three patients groups (NSTEM1, 
STEM1 and UA) (122.00, 106.00 and 124.00 pg/ml respectively) as compared to healthy control group (48.00 
pg/ml). Furthermore; there was no significant differences (p>0.05) in median serum level of OPG among 
patients groups. 
Table-2- Descriptive statistics of RANKL serum level in study groups. 
Study groups RANKL (pg/ml) Median Percentile 25 Percentile 75 
Healthy control 69.25 18.65 109.30 
ACS  patients 31.10 a NS 15.90 68.30 
NSTEMI patients 30.40  aNS 15.90 65.50 
STEMI patients 19.10  aNS,bNS 13.80 59.30 
UA patients 42.20  aNS, bNS, cNS 17.30 73.70 
a= comparison with control; b= comparison with NSTEMI; c= comparison with STEMI. 
 
Table-3- Descriptive statistics of OPG serum level in the study groups. 
Study groups OPG (pg/ml) Median Percentile 25 Percentile 75 
Healthy control 48.00 38.00 67.50 
ACS  patients 122.00 a** 87.50 198.00 
NSTEMI patients 122.00a** 90.00 201.00 
STEMI patients 106.00 a*,bNS 63.00 206.00 
UA patients 124.00 a**,bNS,cNS 98.00 168.00 
* = significant difference (p≤0.05); ** = Highly significant difference (p≤0.001). 
            Determination the ratio of RANKL / OPG in current study revealed significant increase (P<0.001) in the 
ratio of RANKL / OPG in controls (1.26) as compared to patients (0.30). Also there were significant differences 
between three groups of patients and healthy controls. The median RANKL / OPG ratios in NSTEM1, STEM1 
and UA patients groups (0.27, 0.19 and 0.41) were significantly lower (P<0.001) when compared to the ratio in 
healthy controls (1.26).  Meanwhile there were no significant differences in ratio among patients groups 
(p>0.05), according to tables (4). However figure (1) showed no significant correlation between RANKL and 
OPG in patients (P value= 0.533). 
 
Table -4- Descriptive statistics of RANKL /OPG ratio serum level in study groups. 
 
        
Study groups RANKL/OPG Median Percentile 25 Percentile 75 
Healthy control 1.26 0.51 2.11 
ACS  patients 0.30 0.13 0.51 
NSTEMI patients 0.27 a** 0.14 0.38 
STEMI patients 0.19 a*,bNS 0.11 0.50 
UA patients 0.41 a**,bNS,cNS 0.12 0.65 
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Figure-1- Correlation between RANKL and OPG in ACS 
 
Table-5: Descriptive statistics of RANKL, OPG and RANKL / OPG ratio in ACS according to the 
seropositivity of troponin 
 
troponin p value Negative Positive 
OPG (pg/ml) 
Median 126.50 120.00 
0.734NS Percentile 25 98.00 81.50 
Percentile 75 181.50 201.00 
RANKL (pg/ml) 
Median 38.40 27.70 
0.398 NS Percentile 25 16.60 14.85 
Percentile 75 84.50 52.20 
RANKL/OPG 
Median 0.36 0.27 
0.546 NS Percentile 25 0.12 0.14 
Percentile 75 0.65 0.38 
 
4. Discussion 
The findings of the present study indicate that the OPG levels in sera of ACS patients were increased compared 
to controls, whereas the serum RANKL levels were decreased. These results are consistent with other studies 
(Omland et al., 2008; Jono et al., 2010). In this regard, Venuraju and colleagues reported that the OPG 
production has been demonstrated in many different tissues, including bone (osteoblasts), heart and vasculature 
(endothelial and vascular smooth muscle cells). In addition to its presence in connective tissues, OPG also 
circulates in blood at considerably lower concentrations than in tissues (Venuraju et al., 2010). In numerous 
clinical studies, OPG has been consistently reported as a strong independent risk factor and a predictor for the 
onset and severity of both atherosclerosis and cardiovascular disease (Omland et al., 2008).  
On the other hand, Shamsara and co-workers observed that OPG concentration also increases in 
unstable vascular calcifications and other vascular disorders, and they concluded that although OPG can prevent 
the effects of RANKL by anatomization, may be this increment in OPG serum level, as a protective, is not 
enough to neutralize the RANKL effects (Shamsara et al., 2009). At various with present results Rackley et al., 
stated that the serum concentration of RANKL was in the highest level in acute vascular syndromes such as MI 
and ischemic cerebral vascular attacks (Rackley et al., 2009). In addition Giaginis and colleagues documented 
that OPG, but not RANKL levels, were reduced in patients with history of CAD (Giaginis et al., 2012). 
Circulating OPG levels are increased in patients with ACS (Omland et al., 2008), and enhanced 
expression has been found within symptomatic carotid plaques (Golledge et al., 2004). Elevated OPG levels 
have also been associated with the degree of coronary calcification in the general population as a marker of 
coronary atherosclerosis (Abedin et al., 2007). OPG has been reported to predict survival in patients with heart 
failure after acute myocardial infarction (Ueland et al., 2005), to predict heart failure hospitalization and 
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mortality in patients with acute coronary syndrome (Omland et al., 2008), and to be associated with long-term 
mortality in patients with ischemic stroke (Jensen et al., 2010). There are also a few studies that show a 
relationship between OPG and CVD and related mortality in the general population (Semb et al., 2009). 
Moreover, because OPG circulates at much higher levels than RANKL, it may be a more stable overall 
measure of RANKL/RANK activity than soluble RANKL. Therefore, the role of OPG as a marker in CVD may 
not be related to its role as a mediator but reflect its role as a stable marker of activity in the 
RANKL/OPG/RANK axis, as well as the activities in inflammatory pathways that are involved in atherogenesis. 
Moreover, Golledge et al reported OPG to be expressed at higher levels in symptomatic carotid plaques than in 
asymptomatic carotid plaques, and it is possible that the relation between circulating OPG levels and CVD may, 
at least in part, reflect shedding from atherosclerotic lesions. (Golledge et al., 2004). 
The results of present study revealed that there is a significant difference between ACS patients groups 
(UA, NSTEMI and STEMI) and healthy controls according to RANKL /OPG ratio. There was significant 
increase in the ratio of RANKL / OPG in healthy controls as compared to ACS patients. Mohammadpour and 
collegues determined the changes in RANKL and OPG levels concomitantly and reported the results as 
RANKL/OPG ratio. They reported that there was no significant relation between RANKL serum levels and 
coronary artery calcification (CAC), but there was significant negative relation between OPG serum and CAC 
and significant positive relation between RANKL/OPG ratio and CAC. In those patients, the less serum OPG 
levels are, the more calcification intensity occurred; this indicates the protective effects of OPG in vascular 
calcification. According to these facts, they concluded that determination of the RANKl/OPG ratio in compare 
with each of these two factors alone is a better diagnostic indicator for intensity of vascular calcification that 
leads to coronary disorders such as CAC (Mohammadpour et al., 2012). 
Furthermor; Gerber noticed that RANKL/ OPG ratio showed stronger correlation with CAC than either 
RANKL or OPG concentration alone (Gerber, 2009). An imbalance in the RANKL/ OPG molecular triad system 
has been suggested to be responsible for the calcification process of atherosclerotic plaques (Van Campenhout et 
al., 2009). In addition the present study showed no significant correlation between RANKL and OPG in ACS, 
this result disagree with study done by Giaginis et al., who reported that RANKL concentrations showed a strong 
positive correlation with OPG (Giaginis et al., 2012). 
 
5. Conclusion  
These findings indicated that there was high significant elevation in serum level of OPG in acute coronary 
syndrome patients. In addition the present data enforce the clinical utility of OPG in atherosclerosis and 
suggested that RANKL/OPG ratio could be a biomarker for acute coronary syndrome. 
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